Oka N, Tanimoto S, Taue R, Nakatsuji H, Kishimoto T, Izaki H, Fukumori T, Takahashi M, Nishitani M, Kanayama HO: Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci 2006, 97:1093–1098.PubMedCrossRef 57. Dieterle A, Orth R, Daubrawa M, Grotemeier A, Alers S, Ullrich S, Lammers R, Wesselborg S, Stork B: The Akt inhibitor
triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int J Cancer 2009, 125:932–941.PubMedCrossRef 58. Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Maehara Y: Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 2005, 117:376–380.PubMedCrossRef 59. selleck products Kai K, D’Costa S, Sills RC, Kim J: Inhibition of the insulin-like growth factor 1 receptor pathway enhances
the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett 2009, 278:49–55.PubMedCrossRef 60. Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, Moch H, Weder W: PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008, 33:502–506.PubMedCrossRef 61. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, Reusch JE: Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 2000, 275:10761–10766.PubMedCrossRef 62. Manion MK, Hockenbery DM: Targeting BCL-2- related proteins in cancer Venetoclax solubility dmso therapy. Cancer Biol Ther 2003, 2:S105-S114.PubMed 63. Li L, Haynes P, Bender JR: Plasma membrane localization and function of the estrogen receptor α variant (ER46) in human endothelial cells. Proc Natl Acad Sci U S A 2003, 100:4807–4812.PubMedCentralPubMedCrossRef
Competing interests The authors confirm that there are no conflicts of interest. Authors’ contributions BN carried out the majority of the experiments. RS contributed to the FACS analysis. SC, SBa, SBe and FC contributed to interpretation of data and study coordination. RG performed the study design, data acquisition and analysis, and manuscript find more writing. All authors read and approved the final manuscript.”
“Introduction Skin grafting reconstruction is widely used in patients who need surgical removal of cutaneous malignancies, but often leaves unpleasant, antiaesthetic and dystrophic scars. Skin grafting otherwise is mandatory either for oncological follow-up or for the presence of multiple precancerous lesions on the skin surrounding to the area that needs reconstruction. It is also used for wide defect coverage, especially in the facial region, where there are many areas of functional and cosmetic relevance that must be absolutely spared from flap surgery [1].